Executive Summary
The global oligonucleotide synthesis market size is expected to grow from USD 5.33 billion in 2020 to USD 13.15 billion by 2026 at a CAGR of 16.2%.
Based on the product, the market for oligonucleotide synthesis is divided into oligonucleotide-based drugs, synthesized oligonucleotides, reagents, and equipment. In 2020, the oligonucleotide-based drugs segment held the largest share in the oligonucleotide synthesis market. The increasing number of FDA-approved drugs and the rich clinical trial of oligonucleotide-based drugs are expected to further the growth of these therapies in the coming years.
Based on end-users, the oligonucleotide synthesis market is divided into hospitals, pharmaceutical & biotechnology companies, diagnostic laboratories, contract manufacturing organizations (CMOs) and contract research organizations (CROs), and academic research institutes. In 2020, hospitals had the largest share in the oligonucleotide synthesis market. Growth in this market is largely driven by the high number of inpatient and outpatient visits and the great need for oligonucleotide medications to meet the growing demand for patients suffering from rare diseases, neurological disorders, and infectious diseases.
Based on the application, the oligonucleotide synthesis market is divided into therapeutic applications, research applications, and diagnostic applications. In 2020, the therapeutic applications segment had the largest share in the oligonucleotide synthesis market. The increasing use of oligos as therapeutic agents (such as antisense oligos and siRNA) used to treat mood disorders, infections, and genetic abnormalities is expected to further market growth.
In 2020, North America had the largest market share. The region's major share can be attributed to the growth of R&D in health sciences, the growing focus on improving the safety and quality of health care, the increasing demand for high-quality research tools for data retrieval, and the growing focus on developing personalized therapies. The presence of many international players in this region is another important factor contributing to the large distribution of this market segment.
The major players of the oligonucleotide synthesis market are Merck KGaA (Germany), Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Maravai Life Sciences (US), Biogen Inc. (US), LGC Limited (UK), and Sarepta Therapeutics, Inc. (US).
Major factors driving the growth of this market include the increased use of integrated oils in medical programs, increased government funding, and a growing focus on personalized medicine.
COVID-19 is an infectious disease caused by a newly discovered novel coronavirus. Little is known about the outbreak in Wuhan (China) in December 2019, COVID-19 has moved from a regional crisis to a global epidemic. The World Health Organization (WHO) has officially declared the outbreak of COVID-19 as a pandemic. A mix of established pharmaceutical and biopharmaceutical companies, as well as players in the oligonucleotide synthesis market, continue to contribute to global research efforts by providing oligo products for the development of diagnostic, therapeutic, and targeted vaccines targeted by the Coronavirus.
The various efforts of the players in this market and the use of a wide range of oligonucleotide products such as probes and primers in the COVID-19 study have helped researchers better understand Coronavirus. Therefore, COVID-19 had a positive impact on the oligonucleotide synthesis market to some extent. However, by 2020 there was a slight decline in sales of oligonucleotide-based drugs due to restrictions imposed during the COVID-19 violence.
In recent years, governments in various lands have invested heavily in projects related to the field of synthetic biology and genomics. This government investment has played a major role in the development of new technologies. Oligos are an important part of this technology, and increased investment and development in these fields will boost the market growth of oligonucleotides.
Ongoing government-funded projects will lead to advances in genomic technology, particularly DNA sequencing, DNA enlargement, NGS, and genetic expression. Also, the oligos form an integral part of this technology; therefore, an increase in government-funded projects will have a positive impact on the overall growth of the oligonucleotide synthesis market.
The importance of oligo as a preservative has grown significantly in the last decade. Some of the key factors contributing to this growth are increased targeted exposure after human genome identification, development of antisense oligos, and the development of double-stranded siRNA oligo. The therapeutic oligo is also useful in the treatment of diseases caused by viruses, respiratory diseases, cancer, and rare diseases such as Duchenne Muscular Dystrophy (DMD), cystic fibrosis, and thrombotic thrombocytopenic purpura.
However, there have been various cases in the past, where due to high complexity as serious side effects, many drugs have been withdrawn or failed in clinical trials. Such situations may be repetitive and may hinder market growth for some time.
Countries such as China, India, Singapore, and emerging economies such as Brazil offer significant growth opportunities in the oligonucleotide synthesis markets. These strengths are mainly due to the growth of R&D investment by various emerging economic companies in the Asia Pacific and Latin America regions.
The use of genetic therapies and antisense therapies to reverse tumor regression is well documented in diagnostic and clinical settings. However, translating this into general clinical applications remains an obstacle. Major challenges in cancer treatment genetics and antisense treatment are the lack of delivery systems that effectively deliver a dose of gene therapy or antidepressant to a targeted tumor. Delivery of Antisense drugs to remote treatment tumors is a difficult task that promotes the development of delivery vectors that can overcome many obstacles. Many scientists have used viral and non-viral vectors to deliver a therapeutic gene or antisense compound to target cells or tissues. Although the results of early gene therapy and clinical trials based on antisense treatment using viruses or non-viral vectors have been encouraging, it is still difficult to find a one-size-fits-all approach to appropriate gene transfer and vector expression.
The limitations of current vector technology have hampered the advancement of gene therapy and anti-cancer treatment in the clinic. Therefore, the development of appropriate delivery systems to identify genetic therapies and antisense targeted cells and tissues is one of the possible alternatives that should be further explored in the future to increase genetic therapy and antisense treatment against many types of cancer.
-
Revenue Share (%), By Product (2019) -
Revenue Share (%), By Application (2019) -
Revenue Share (%), By End-user (2019) -
Revenue Share (%), By Region (2019)
